Clinical trials
Recurrent or Metastatic Cervical Cancer clinical trials
Below are recruiting recurrent or metastatic cervical cancer clinical trials, each written for real people, not researchers. We’re tracking 3,848 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04105270RecruitingPhase 2
Durvalumab plus chemo with RMT for lung cancer
This Phase 2 trial studies a new treatment plan that combines RMT with durvalumab and chemotherapy in people with untreated advanced lung adenocarcinoma. It aims to improve outcomes by helping the immune system and fighting cancer cells together.
Phoenix, ArizonaAges 18 years+ - NCT04134559RecruitingPhase 2
Pembrolizumab for kids with liver cancer that came back
This trial studies pembrolizumab (an immune therapy) in children and young people with hepatocellular carcinoma (HCC) that has returned or did not respond to earlier treatment. The goal is to see whether it can shrink tumors and help control the cancer.
San Francisco, CaliforniaAges birth–30 years - NCT03988283RecruitingPhase 1
Personalized DNA vaccine for recurrent childhood brain tumors
This trial tests a personalized DNA vaccine made from your tumor’s DNA (neoantigens) to help your immune system fight the cancer. It is designed for children and young adults with certain recurrent or newly diagnosed brain/spine tumors, after they have had other standard treatments and tumor tissue is available for testing.
St Louis, MissouriAges Up to 25 years - NCT03907826RecruitingPhase 3
PD-1 therapy plus chemoradiation for recurrent nasopharyngeal cancer
This trial studies whether adding a PD-1 antibody (an immunotherapy) to standard chemoradiation can better control recurrent nasopharyngeal cancer that can’t be removed with surgery. If you qualify, you’d receive the study treatment and be closely monitored for side effects and cancer response.
Guangzhou, GuangdongAges 18–70 - NCT03998202Recruiting
Study of chemotherapy side effects in older colorectal cancer patients
This study looks at how chemotherapy and immunotherapy affect the body in older adults with colorectal cancer, especially early side effects. It may help researchers understand why some people lose strength and how to better predict and manage treatment toxicity.
Millville, DelawareAges 60 years+ - NCT03936478RecruitingPhase 2
MRI-guided partial breast radiation in three short treatments
This study tests a faster, targeted type of radiation for early breast cancer, using real-time MRI to help plan and guide treatment. It may help deliver the same cancer-fighting effect while limiting radiation to the rest of the breast.
Madison, WisconsinAges 40 years+ - NCT03862677Recruiting
Testing immune markers to predict outcomes in ovarian cancer
This study looks at immune-related markers in people with ovarian cancer to see if they can help predict prognosis (how the cancer may behave). If you qualify, your doctors may use your immune test results alongside other standard treatments like surgery, chemotherapy, and/or immunotherapy.
LeidenAges 18 years+ - NCT03874052RecruitingPhase 1
Ruxolitinib plus venetoclax and azacitidine for relapsed AML
This early-phase study tests a combination of ruxolitinib with venetoclax, with or without azacitidine, for adults whose acute myeloid leukemia (AML) has come back or does not respond to treatment. It may help by stopping cancer cells from growing and improving blood counts, with the exact plan guided by the study arm you’re assigned to.
Columbus, OhioAges 18 years+ - NCT03832361RecruitingPhase 2
Mirvetuximab for folate-receptor–positive endometrial cancer
This Phase 2 study tests mirvetuximab (a targeted antibody drug) in women whose endometrial cancer is positive for folate receptor-alpha. It aims to shrink tumors and improve outcomes, especially in cancer that has returned or kept growing after previous treatment.
New Haven, ConnecticutAges 18–100 - NCT03562741Recruiting
Tracking outcomes of fecal transplant for repeated C. difficile
This study looks at how fecal microbiota transplantation (a transplant of healthy gut bacteria) works for people who get C. difficile infection repeatedly. It also focuses on collecting follow-up information to better understand which patients benefit and how.
Worcester, MassachusettsAges 16 years+ - NCT03516708RecruitingPhase 1/Phase 2
Epacadostat with pre-op radiation for locally advanced rectal cancer
This trial studies whether adding epacadostat (a cancer drug) to standard pre-operative chemoradiation can improve outcomes for people with locally advanced rectal cancer. It’s designed to see if the added treatment is safe and potentially more effective before surgery.
Orange, CaliforniaAges 18 years+ - NCT03459820Enrolling by invitationPhase 2/Phase 3
PET/CT scan study for high-risk or returning prostate cancer
This trial studies how a special PET/CT scan (using 18F-DCFPyL) helps evaluate prostate cancer that is either high-risk at diagnosis or has come back based on PSA blood tests. It may help your care team better stage (map) the cancer and guide next steps.
Montreal, QuebecAges 18 years+ - NCT03454035RecruitingPhase 1
Combination of two study drugs for advanced pancreatic and other solid tumors
This trial tests two drugs, ulixertinib and palbociclib, taken together to see if they can shrink tumors in patients with advanced pancreatic cancer, melanoma, or other solid tumors. It may be an option for people who have already tried standard treatments.
Chapel Hill, North CarolinaAges 18–99 - NCT03219450RecruitingPhase 1
Personalized vaccine for early-stage, treatment-free CLL
This Phase 1 study tests a personalized cancer vaccine made from each patient’s CLL (“neoantigens”) plus a medicine called poly-ICLC to help the immune system learn to recognize the cancer. It is designed for people who have CLL but are currently not needing treatment, to see if it’s safe and may help keep the disease under control.
Boston, MassachusettsAges 18 years+ - NCT03114462RecruitingPhase 1
Study of focused radiation for laryngeal cancer
This Phase 1 study tests a precise type of radiation treatment for people with certain stages of laryngeal (voice box) squamous cell cancer. The goal is to see how safe the treatment is and how well it may work in shrinking or controlling the cancer while aiming to preserve the larynx.
Houston, TexasAges 18 years+ - NCT02813135RecruitingPhase 1/Phase 2
Targeted cancer treatment chosen by a tumor’s genetic findings
This early-phase trial tests a treatment plan that uses results from genetic testing of your tumor to choose the best targeted therapy. It may help people whose cancer has come back or does not respond to standard treatment by matching treatment to specific tumor changes.
CopenhagenAges Up to 18 years - NCT07881666RecruitingPhase 1
Vaccine for bladder cancer after standard treatment fails
This study tests an investigational vaccine for people with a type of bladder cancer that has come back after receiving standard treatments (BCG or chemotherapy into the bladder). The vaccine is designed to help the immune system fight the cancer. It may be an option if your cancer is limited to the lining of the bladder and you are otherwise in good health.
Kfar Saba, Central DistrictAges 18 years+ - NCT07144254RecruitingPhase 1
Tegavivint and gemcitabine for relapsed osteosarcoma
This trial tests a new drug called tegavivint combined with the chemotherapy drug gemcitabine for people whose osteosarcoma has come back or stopped responding to treatment. The goal is to see if this combination can help shrink or control the cancer.
Atlanta, GeorgiaAges 1–30 - NCT06709534Recruiting
Exercise program for gynecologic cancer survivors
This study tests a personalized at-home exercise program designed for gynecologic cancer survivors who have finished treatment. The goal is to see if it can help you feel better and improve symptoms.
Atlanta, GeorgiaAges 18 years+ - NCT07326566RecruitingPhase 2
Silevertinib and chemo for a type of glioblastoma
This trial tests a new drug, silevertinib, combined with temozolomide (a chemotherapy) for people with a newly diagnosed glioblastoma that has certain genetic markers. It aims to see if this combination works better than standard treatment for tumors with these specific features.
Birmingham, AlabamaAges 18 years+ - NCT07060807RecruitingPhase 3
Patritumab deruxtecan for advanced breast cancer
This study tests an investigational drug called patritumab deruxtecan for people with a certain type of advanced breast cancer that is hormone receptor-positive and HER2-negative. The drug targets a protein called HER3, which is common on these cancer cells, and may slow or shrink the cancer when previous treatments have stopped working.
Daphne, AlabamaAges 18 years+ - NCT02523014RecruitingPhase 2
Drug combo for meningioma that keeps growing despite treatment
This Phase 2 trial tests several targeted medicines (given together or by specific assignment) for meningiomas inside the brain that are progressing or not fully removed after surgery. It may help slow the tumor’s growth and improve symptoms by blocking tumor growth pathways.
Birmingham, AlabamaAges 18 years+ - NCT06263647Recruiting
Program to reduce repeat gun violence injuries
This study tests a hospital-based program to help people who have been shot due to community violence avoid future injuries. Participants will get support and resources to reduce the risk of repeat violence.
Houston, TexasAges 16–40 - NCT07133997RecruitingPhase 1
Combination therapy for relapsed CD19+ B-cell leukemia
This trial tests a new combination of three drugs for patients with relapsed or treatment-resistant CD19-positive B-cell acute lymphoblastic leukemia. It aims to see if adding the drugs venetoclax and asparaginase to blinatumomab can improve outcomes.
Duarte, CaliforniaAges 12–55
Hear when a new Recurrent or Metastatic Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic cervical cancer?
- Yes. Clin2 currently lists 3,848 recruiting recurrent or metastatic cervical cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic cervical cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic cervical cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.